Table of Contents
1 Report Overview
1.1 Research Scope
1.2 Top Bacterial Vaginosis Drug Manufacturers Covered: Ranking by Revenue
1.3 Market Segment by Type
1.3.1 Global Bacterial Vaginosis Drug Market Size by Type: 2015 VS 2020 VS 2026 (US$ Million)
1.3.2 Rx
1.3.3 OTC
1.4 Market Segment by Application
1.4.1 Global Bacterial Vaginosis Drug Consumption by Application: 2015 VS 2020 VS 2026
1.4.2 Hospital
1.4.3 Pharmacy
1.4.4 Other
1.5 Study Objectives
1.6 Years Considered
2 Global Market Perspective
2.1 Global Bacterial Vaginosis Drug Revenue (2015-2026)
2.1.1 Global Bacterial Vaginosis Drug Revenue (2015-2026)
2.1.2 Global Bacterial Vaginosis Drug Sales (2015-2026)
2.2 Bacterial Vaginosis Drug Market Size across Key Geographies Worldwide: 2015 VS 2020 VS 2026
2.2.1 Global Bacterial Vaginosis Drug Sales by Regions (2015-2020)
2.2.2 Global Bacterial Vaginosis Drug Revenue by Regions (2015-2020)
2.3 Global Top Bacterial Vaginosis Drug Regions (Countries) Ranking by Market Size
2.4 Bacterial Vaginosis Drug Industry Trends
2.4.1 Bacterial Vaginosis Drug Market Top Trends
2.4.2 Market Drivers
2.4.3 Bacterial Vaginosis Drug Market Challenges
2.4.4 Porter’s Five Forces Analysis
2.4.5 Primary Interviews with Key Bacterial Vaginosis Drug Players: Views for Future
3 Competitive Landscape by Manufacturers
3.1 Global Top Bacterial Vaginosis Drug Manufacturers by Sales (2015-2020)
3.1.1 Global Bacterial Vaginosis Drug Sales by Manufacturers (2015-2020)
3.1.2 Global Bacterial Vaginosis Drug Sales Market Share by Manufacturers (2015-2020)
3.1.3 Global 5 and 10 Largest Manufacturers by Bacterial Vaginosis Drug Sales in 2019
3.2 Global Top Manufacturers Bacterial Vaginosis Drug by Revenue
3.2.1 Global Bacterial Vaginosis Drug Revenue by Manufacturers (2015-2020)
3.2.2 Global Bacterial Vaginosis Drug Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Bacterial Vaginosis Drug Market Concentration Ratio (CR5 and HHI)
3.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Bacterial Vaginosis Drug as of 2019)
3.4 Global Bacterial Vaginosis Drug Average Selling Price (ASP) by Manufacturers
3.5 Key Manufacturers Bacterial Vaginosis Drug Plants/Factories Distribution and Area Served
3.6 Date of Key Manufacturers Enter into Bacterial Vaginosis Drug Market
3.7 Key Manufacturers Bacterial Vaginosis Drug Product Offered
3.8 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Bacterial Vaginosis Drug Historic Market Review by Type (2015-2020)
4.1.2 Global Bacterial Vaginosis Drug Sales Market Share by Type (2015-2020)
4.1.3 Global Bacterial Vaginosis Drug Revenue Market Share by Type (2015-2020)
4.1.4 Bacterial Vaginosis Drug Price by Type (2015-2020)
4.1 Global Bacterial Vaginosis Drug Market Estimates and Forecasts by Type (2021-2026)
4.2.2 Global Bacterial Vaginosis Drug Sales Forecast by Type (2021-2026)
4.2.3 Global Bacterial Vaginosis Drug Revenue Forecast by Type (2021-2026)
4.2.4 Bacterial Vaginosis Drug Price Forecast by Type (2021-2026)
5 Global Bacterial Vaginosis Drug Market Size by Application
5.1 Global Bacterial Vaginosis Drug Historic Market Review by Application (2015-2020)
5.1.2 Global Bacterial Vaginosis Drug Sales Market Share by Application (2015-2020)
5.1.3 Global Bacterial Vaginosis Drug Revenue Market Share by Application (2015-2020)
5.1.4 Bacterial Vaginosis Drug Price by Application (2015-2020)
5.2 Global Bacterial Vaginosis Drug Market Estimates and Forecasts by Application (2021-2026)
5.2.2 Global Bacterial Vaginosis Drug Sales Forecast by Application (2021-2026)
5.2.3 Global Bacterial Vaginosis Drug Revenue Forecast by Application (2021-2026)
5.2.4 Bacterial Vaginosis Drug Price Forecast by Application (2021-2026)
6 North America
6.1 North America Bacterial Vaginosis Drug Breakdown Data by Company
6.2 North America Bacterial Vaginosis Drug Breakdown Data by Type
6.3 North America Bacterial Vaginosis Drug Breakdown Data by Application
6.4 North America Bacterial Vaginosis Drug Breakdown Data by Countries
6.4.1 North America Bacterial Vaginosis Drug Sales by Countries
6.4.2 North America Bacterial Vaginosis Drug Revenue by Countries
6.4.3 U.S.
6.4.4 Canada
7 Europe
7.1 Europe Bacterial Vaginosis Drug Breakdown Data by Company
7.2 Europe Bacterial Vaginosis Drug Breakdown Data by Type
7.3 Europe Bacterial Vaginosis Drug Breakdown Data by Application
7.4 Europe Bacterial Vaginosis Drug Breakdown Data by Countries
7.4.1 Europe Bacterial Vaginosis Drug Sales by Countries
7.4.2 Europe Bacterial Vaginosis Drug Revenue by Countries
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
8 Asia Pacific
8.1 Asia Pacific Bacterial Vaginosis Drug Breakdown Data by Company
8.2 Asia Pacific Bacterial Vaginosis Drug Breakdown Data by Type
8.3 Asia Pacific Bacterial Vaginosis Drug Breakdown Data by Application
8.4 Asia Pacific Bacterial Vaginosis Drug Breakdown Data by Regions
8.4.1 Asia Pacific Bacterial Vaginosis Drug Sales by Regions
8.4.2 Asia Pacific Bacterial Vaginosis Drug Revenue by Regions
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 India
8.4.7 Australia
8.4.8 Taiwan
8.4.9 Indonesia
8.4.10 Thailand
8.4.11 Malaysia
8.4.12 Philippines
8.4.13 Vietnam
9 Latin America
9.1 Latin America Bacterial Vaginosis Drug Breakdown Data by Company
9.2 Latin America Bacterial Vaginosis Drug Breakdown Data by Type
9.3 Latin America Bacterial Vaginosis Drug Breakdown Data by Application
9.4 Latin America Bacterial Vaginosis Drug Breakdown Data by Countries
9.4.1 Latin America Bacterial Vaginosis Drug Sales by Countries
9.4.2 Latin America Bacterial Vaginosis Drug Revenue by Countries
9.4.3 Mexico
9.4.4 Brazil
9.4.5 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Bacterial Vaginosis Drug Breakdown Data by Type
10.2 Middle East and Africa Bacterial Vaginosis Drug Breakdown Data by Application
10.3 Middle East and Africa Bacterial Vaginosis Drug Breakdown Data by Countries
10.3.1 Middle East and Africa Bacterial Vaginosis Drug Sales by Countries
10.3.2 Middle East and Africa Bacterial Vaginosis Drug Revenue by Countries
10.3.3 Turkey
10.3.4 Saudi Arabia
10.3.5 U.A.E
11 Company Profiles
11.1 Bayer
11.1.1 Bayer Corporation Information
11.1.2 Bayer Business Overview and Total Revenue (2019 VS 2018)
11.1.3 Bayer Bacterial Vaginosis Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.1.4 Bayer Bacterial Vaginosis Drug Products and Services
11.1.5 Bayer SWOT Analysis
11.1.6 Bayer Recent Developments
11.2 Pfizer
11.2.1 Pfizer Corporation Information
11.2.2 Pfizer Business Overview and Total Revenue (2019 VS 2018)
11.2.3 Pfizer Bacterial Vaginosis Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.2.4 Pfizer Bacterial Vaginosis Drug Products and Services
11.2.5 Pfizer SWOT Analysis
11.2.6 Pfizer Recent Developments
11.3 Sanofi
11.3.1 Sanofi Corporation Information
11.3.2 Sanofi Business Overview and Total Revenue (2019 VS 2018)
11.3.3 Sanofi Bacterial Vaginosis Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.3.4 Sanofi Bacterial Vaginosis Drug Products and Services
11.3.5 Sanofi SWOT Analysis
11.3.6 Sanofi Recent Developments
11.4 Piramal
11.4.1 Piramal Corporation Information
11.4.2 Piramal Business Overview and Total Revenue (2019 VS 2018)
11.4.3 Piramal Bacterial Vaginosis Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.4.4 Piramal Bacterial Vaginosis Drug Products and Services
11.4.5 Piramal SWOT Analysis
11.4.6 Piramal Recent Developments
11.5 Abbott
11.5.1 Abbott Corporation Information
11.5.2 Abbott Business Overview and Total Revenue (2019 VS 2018)
11.5.3 Abbott Bacterial Vaginosis Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.5.4 Abbott Bacterial Vaginosis Drug Products and Services
11.5.5 Abbott SWOT Analysis
11.5.6 Abbott Recent Developments
11.6 Galderma
11.6.1 Galderma Corporation Information
11.6.2 Galderma Business Overview and Total Revenue (2019 VS 2018)
11.6.3 Galderma Bacterial Vaginosis Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.6.4 Galderma Bacterial Vaginosis Drug Products and Services
11.6.5 Galderma SWOT Analysis
11.6.6 Galderma Recent Developments
11.7 Mission
11.7.1 Mission Corporation Information
11.7.2 Mission Business Overview and Total Revenue (2019 VS 2018)
11.7.3 Mission Bacterial Vaginosis Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.7.4 Mission Bacterial Vaginosis Drug Products and Services
11.7.5 Mission SWOT Analysis
11.7.6 Mission Recent Developments
11.8 Alkem
11.8.1 Alkem Corporation Information
11.8.2 Alkem Business Overview and Total Revenue (2019 VS 2018)
11.8.3 Alkem Bacterial Vaginosis Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.8.4 Alkem Bacterial Vaginosis Drug Products and Services
11.8.5 Alkem SWOT Analysis
11.8.6 Alkem Recent Developments
11.9 Xiuzheng
11.9.1 Xiuzheng Corporation Information
11.9.2 Xiuzheng Business Overview and Total Revenue (2019 VS 2018)
11.9.3 Xiuzheng Bacterial Vaginosis Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.9.4 Xiuzheng Bacterial Vaginosis Drug Products and Services
11.9.5 Xiuzheng SWOT Analysis
11.9.6 Xiuzheng Recent Developments
11.10 Teva
11.10.1 Teva Corporation Information
11.10.2 Teva Business Overview and Total Revenue (2019 VS 2018)
11.10.3 Teva Bacterial Vaginosis Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.10.4 Teva Bacterial Vaginosis Drug Products and Services
11.10.5 Teva SWOT Analysis
11.10.6 Teva Recent Developments
11.11 Perrigo
11.11.1 Perrigo Corporation Information
11.11.2 Perrigo Business Overview and Total Revenue (2019 VS 2018)
11.11.3 Perrigo Bacterial Vaginosis Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.11.4 Perrigo Bacterial Vaginosis Drug Products and Services
11.11.5 Perrigo SWOT Analysis
11.11.6 Perrigo Recent Developments
11.12 West-Ward
11.12.1 West-Ward Corporation Information
11.12.2 West-Ward Business Overview and Total Revenue (2019 VS 2018)
11.12.3 West-Ward Bacterial Vaginosis Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.12.4 West-Ward Bacterial Vaginosis Drug Products and Services
11.12.5 West-Ward SWOT Analysis
11.12.6 West-Ward Recent Developments
11.13 HPGC
11.13.1 HPGC Corporation Information
11.13.2 HPGC Business Overview and Total Revenue (2019 VS 2018)
11.13.3 HPGC Bacterial Vaginosis Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.13.4 HPGC Bacterial Vaginosis Drug Products and Services
11.13.5 HPGC SWOT Analysis
11.13.6 HPGC Recent Developments
11.14 Yunnan Baiyao
11.14.1 Yunnan Baiyao Corporation Information
11.14.2 Yunnan Baiyao Business Overview and Total Revenue (2019 VS 2018)
11.14.3 Yunnan Baiyao Bacterial Vaginosis Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.14.4 Yunnan Baiyao Bacterial Vaginosis Drug Products and Services
11.14.5 Yunnan Baiyao SWOT Analysis
11.14.6 Yunnan Baiyao Recent Developments
11.15 Starpharma
11.15.1 Starpharma Corporation Information
11.15.2 Starpharma Business Overview and Total Revenue (2019 VS 2018)
11.15.3 Starpharma Bacterial Vaginosis Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.15.4 Starpharma Bacterial Vaginosis Drug Products and Services
11.15.5 Starpharma SWOT Analysis
11.15.6 Starpharma Recent Developments
11.16 Novel
11.16.1 Novel Corporation Information
11.16.2 Novel Business Overview and Total Revenue (2019 VS 2018)
11.16.3 Novel Bacterial Vaginosis Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.16.4 Novel Bacterial Vaginosis Drug Products and Services
11.16.5 Novel SWOT Analysis
11.16.6 Novel Recent Developments
11.17 Edenvridge
11.17.1 Edenvridge Corporation Information
11.17.2 Edenvridge Business Overview and Total Revenue (2019 VS 2018)
11.17.3 Edenvridge Bacterial Vaginosis Drug Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.17.4 Edenvridge Bacterial Vaginosis Drug Products and Services
11.17.5 Edenvridge SWOT Analysis
11.17.6 Edenvridge Recent Developments
12 Supply Chain and Sales Channels Analysis
12.1 Supply Chain Analysis
12.2 Sales Channels Analysis
12.2.1 Bacterial Vaginosis Drug Sales Channels
12.2.2 Bacterial Vaginosis Drug Distributors
12.3 Bacterial Vaginosis Drug Customers
13 Estimates and Projections by Regions (2021-2026)
13.1 Global Bacterial Vaginosis Drug Sales Forecast (2021-2026)
13.1.1 Global Bacterial Vaginosis Drug Sales Forecast by Regions (2021-2026)
13.1.2 Global Bacterial Vaginosis Drug Revenue Forecast by Regions (2021-2026)
13.2 North America Market Size Forecast (2021-2026)
13.2.1 North America Bacterial Vaginosis Drug Sales Forecast (2021-2026)
13.2.2 North America Bacterial Vaginosis Drug Revenue Forecast (2021-2026)
13.2.3 North America Bacterial Vaginosis Drug Size Forecast by County (2021-2026)
13.3 Europe Market Size Forecast (2021-2026)
13.3.1 Europe Bacterial Vaginosis Drug Sales Forecast (2021-2026)
13.3.2 Europe Bacterial Vaginosis Drug Revenue Forecast (2021-2026)
13.3.3 Europe Bacterial Vaginosis Drug Size Forecast by County (2021-2026)
13.4 Asia Pacific Market Size Forecast (2021-2026)
13.4.1 Asia Pacific Bacterial Vaginosis Drug Sales Forecast (2021-2026)
13.4.2 Asia Pacific Bacterial Vaginosis Drug Revenue Forecast (2021-2026)
13.4.3 Asia Pacific Bacterial Vaginosis Drug Size Forecast by Region (2021-2026)
13.5 Latin America Market Size Forecast (2021-2026)
13.5.1 Latin America Bacterial Vaginosis Drug Sales Forecast (2021-2026)
13.5.2 Latin America Bacterial Vaginosis Drug Revenue Forecast (2021-2026)
13.5.3 Latin America Bacterial Vaginosis Drug Size Forecast by County (2021-2026)
13.6 Middle East and Africa Market Forecast
13.6.1 Middle East and Africa Bacterial Vaginosis Drug Sales Forecast (2021-2026)
13.6.2 Middle East and Africa Bacterial Vaginosis Drug Revenue Forecast (2021-2026)
13.6.3 Middle East and Africa Bacterial Vaginosis Drug Size Forecast by County (2021-2026)
14 Research Findings and Conclusion
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer
【掲載企業】
Bayer、Pfizer、Sanofi、Piramal、Abbott、Galderma、Mission、Alkem、Xiuzheng、Teva、Perrigo、West-Ward、HPGC、Yunnan Baiyao、Starpharma、Novel、Edenvridge
【免責事項】
https://www.globalresearch.jp/disclaimer